CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights.
The company specializes in developing RNA-targeted therapies to upregulate gene expression to effectively treat genetic diseases.
Q1 2026:
The company reported a net loss of $18.33 million, or $0.32 per share, in Q1 2026, while in the same period of 2025, the net loss was $12.43 million, or $0.62 per share.
Research and development expenses (R&D) were $10.16 million, relatively stable compared to $10.15 million in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $99.21 million.
Business Updates:
CAMP4 submitted a regulatory filing in Australia to enable a Phase 1/2 clinical trial for CMP-002 in the second half of 2026. CMP-002, a first-in-class treatment for SYNGAP1-related disorders, was also granted an orphan drug designation by the European Medicines Agency (EMA) and filed to receive an orphan drug designation from the FDA.
The company also began a collaboration with CURE SYNGAP for the ProMMis study to determine the natural history of SYNGAP1-related disorders and to develop effective therapies.
A preprint of a pioneering study was submitted, outlining regRNA capture sequencing to create the largest catalog of regRNAs.
CAMP is currently trading at $4.27, down 1.50%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.